Bioretec Oy (HEL:BRETEC)
| Market Cap | 28.18M -48.5% |
| Revenue | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 1.34B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,808,777 |
| Open | 0.0220 |
| Previous Close | 0.0216 |
| Day's Range | 0.0210 - 0.0220 |
| 52-Week Range | 0.0108 - 1.8950 |
| Beta | 0.68 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 15, 2026 |
About Bioretec Oy
Bioretec Oy, a medical device company, develops, manufactures, and markets bioresorbable orthopedic implants for the repair of bone and soft tissue injuries in children and adults worldwide. The company offers Activa IM-Nail, a bioabsorbable option for pediatric forearm intramedullary nailing; ActivaNail, an implant that is be used in upper or lower limbs to ensure successful bone regeneration; ActivaPin, a bioabsorbable implant for upper and lower limb fractures; and ActivaScrew, an absorbable surgical implant that is used in fracture treatmen... [Read more]
News
Bioretec Oy Earnings release: Q1 2026
Bioretec Oy released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
Bioretec Oy Earnings Call Transcript: Q4 2025
2025 was a transformative year with leadership changes, strategic resets, and strong regulatory wins. U.S. direct sales grew over 60% quarter-over-quarter, but total revenue dipped due to distribution model changes and one-off items. Focus remains on commercial growth and capital strengthening.
Bioretec Oy Quarterly report: Q4 2025
Bioretec Oy has published its Q4 2025 quarterly earnings report on February 13, 2026.
Bioretec Oy Slides: Q4 2025
Bioretec Oy has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 13, 2026.
Bioretec Oy Annual report: Q4 2025
Bioretec Oy has published its Q4 2025 annual report on February 13, 2026.
Bioretec Ltd (OHEL:BRETEC) Q4 2025 Earnings Report Preview: What To Expect
Bioretec Ltd (OHEL:BRETEC) Q4 2025 Earnings Report Preview: What To Expect
Bioretec Board Approves Updated Strategy, Financial Targets For 2026-2028 Period
(RTTNews) - Bioretec (0TN.F, BRETEC.HE) said Board of Directors has approved the company's updated strategy for 2026-2028 and new financial targets for the strategy period. Bioretec's new financial ta...
Bioretec Secures FDA Breakthrough Device Designation For RemeOs DrillPin
(RTTNews) - Bioretec Oy (0TN.F, BRETEC.HE) has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its magnesium alloy technology-based, biodegradable RemeO...
Bioretec Oy Earnings release: Q3 2025
Bioretec Oy released its Q3 2025 earnings on November 13, 2025, summarizing the period's financial results.
Bioretec Oy Quarterly report: Q2 2025
Bioretec Oy has published its Q2 2025 quarterly earnings report on August 14, 2025.
Bioretec Ltd's business review Q1 2025: Strong net sales in the first quarter; CE approval with comprehensive indications received in January accelerates the future expansion of RemeOs products
Bioretec Ltd Company announcement 15 May 2025 at 8:00 a.m. TAMPERE, Finland , May 15, 2025 /PRNewswire/ -- This announcement summarizes Bioretec Ltd's business review for January- March 2025 . The com...